mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2026-3-84-90mrj-2003Research ArticleОБЗОРЫREVIEWSАгонисты рецептора глюкагоноподобного пептида 1 как потенциальный путь преодоления резистентности к терапии при псориазе и псориатическом артритеGlucagon-like peptide 1 receptor agonists as a potential way to overcome treatment resistance in psoriasis and psoriatic arthritishttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А

125993, Москва, ул. Баррикадная, 2/1, стр. 1; 

34A, Kashirskoe Shosse, Moscow 115522 

2/1, Barrikadnaya Street, Build. 1, Moscow 125993 

https://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34А; 

34A, Kashirskoe Shosse, Moscow 115522 

https://orcid.org/0000-0002-5290-156XПаневинТ. С.PanevinT. S.

Тарас Сергеевич Паневин

115522, Москва, Каширское шоссе, 34А

680000, Хабаровск, ул. Муравьева-Амурского, 35 

Taras Sergeevich Panevin

34A, Kashirskoe Shosse, Moscow 115522 

35, Muravyeva-Amurskogo Street, Khabarovsk 680000 

tarasel@list.ruhttps://orcid.org/0000-0002-4579-2836ЗоткинЕ. Г.ZotkinE. G.

115522, Москва, Каширское шоссе, 34А; 

34A, Kashirskoe Shosse, Moscow 115522 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Far Eastern State Medical University, Ministry of Health of RussiaRussian Federation2026240620262038490Copyright © Лила А.М., Коротаева Т.В., Паневин Т.С., Зоткин Е.Г., 20262026Лила А.М., Коротаева Т.В., Паневин Т.С., Зоткин Е.Г.Lila A.M., Korotaeva T.V., Panevin T.S., Zotkin E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/2003

Пациенты с псориазом (ПсО) и псориатическим артритом (ПсА) характеризуются высокой частотой сопутствующего ожирения и метаболических нарушений, а увеличение индекса массы тела (ИМТ) повышает вероятность развития ПсА у пациентов с ПсО. Наличие ожирения, как и наличие ПсО/ПсА, ассоциируется с увеличением сердечно-сосудистого риска и ухудшением качества жизни. Достижение минимальной активности ПсО/ПсА у пациентов с ожирением может быть затруднено. Эффективное и стойкое снижение ИМТ (независимо от способа) ведет к увеличению вероятности наступления ремиссии и повышает эффективность ингибиторов фактора некроза опухоли α (ФНОα). В настоящем обзоре представлены результаты исследований влияния наиболее часто используемой группы препаратов для лечения ожирения – агонистов рецептора глюкагоноподобного пептида 1 на активность ПсО/ПсА, а также их комбинированного применения с генно-инженерными биологическими препаратами. 

Patients with psoriasis (PsO) and psoriatic arthritis (PsA) are characterized by a high prevalence of concomitant obesity and metabolic disorders, and an increased body mass index (BMI) increases the likelihood of PsA development in patients with PsO. Obesity, as well as PsO/PsA, is associated with increased cardiovascular risk and reduced quality of life. Achieving minimal disease activity in PsO/PsA in obese patients may be challenging. Effective and sustained BMI reduction (regardless of the method) increases the likelihood of achieving remission and enhances the efficacy of tumor necrosis factor α (TNFα) inhibitors.

This review presents the results of studies on the effects of the most commonly used drug class for obesity treatment — glucagon-like peptide 1 receptor agonists — on PsO/PsA activity, as well as their combined use with biologic agents. 

псориазпсориатический артритожирениеметаболический синдромтирзепатидсемаглутидлираглутидиксекизумабpsoriasispsoriatic arthritisobesitymetabolic syndrometirzepatidesemaglutideliraglutideixekizumabReferencesКруглова ЛС, Бакулев АЛ, Коротаева ТВ и др. Псориаз. Москва: ГЭОТАР-Медиа; 2022. 328 с.Kruglova LS, Bakulev AL, Korotaeva TV, et al. Psoriasis. Moscow: GEOTAR-Media; 2022. 328 p.Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9; 376(10):957-970. doi: 10.1056/NEJMra 1505557.Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9; 376(10):957-970. doi: 10.1056/NEJMra 1505557.Scarpa R. Psoriatic Syndrome or Psoriatic Disease? J Rheumatol. 2020 Jun 1;47(6):941. doi: 10.3899/jrheum.200051.Scarpa R. Psoriatic Syndrome or Psoriatic Disease? J Rheumatol. 2020 Jun 1;47(6):941. doi: 10.3899/jrheum.200051.Sheth S, Inestroza K, Merola JF, et al. Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network. J Psoriasis Psoriatic Arthritis. 2025 May 28; 10(4):124-130. doi: 10.1177/2475530 3251337020.Sheth S, Inestroza K, Merola JF, et al. Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network. J Psoriasis Psoriatic Arthritis. 2025 May 28; 10(4):124-130. doi: 10.1177/2475530 3251337020.Reaven P. Metabolic syndrome. J Insur Med. 2004;36(2):132-42.Reaven P. Metabolic syndrome. J Insur Med. 2004;36(2):132-42.Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. Diab Vasc Dis Res. 2004 Oct;1(2):68-75. doi: 10.3132/dvdr.2004.010.Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. Diab Vasc Dis Res. 2004 Oct;1(2):68-75. doi: 10.3132/dvdr.2004.010.Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006 Nov;55(5):829-35. doi: 10.1016/j.jaad.2006.08.040. Epub 2006 Sep 25.Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006 Nov;55(5):829-35. doi: 10.1016/j.jaad.2006.08.040. Epub 2006 Sep 25.Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012 Dec 3;2(12):e54. doi: 10.1038/nutd.2012.26.Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012 Dec 3;2(12):e54. doi: 10.1038/nutd.2012.26.Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017 Dec;137(12): 2484-2490. doi: 10.1016/j.jid.2017.07.822.Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017 Dec;137(12): 2484-2490. doi: 10.1016/j.jid.2017.07.822.Корсакова ЮЛ, Коротаева ТВ, Логинова ЕЮ и др. Клинико-инструментальная характеристика псориатического артрита у мужчин и женщин. Данные когортного наблюдательного исследования. Терапевтический архив. 2024;96(5):479-485.Korsakova YuL, Korotaeva TV, Loginova EYu, et al. Clinical and instrumental characteristics of psoriatic arthritis in men and women. Data from a cohort observational study. Terapevticheskii arkhiv. 2024;96(5):479-485. (In Russ.).Корсакова ЮЛ, Коротаева ТВ, Логинова ЕЮ и др. Взаимосвязь ожирения, кардиометаболических нарушений и активности заболевания у больных псориатическим артритом: данные Общероссийского регистра. Терапевтический архив. 2021;93(5):573-580.Korsakova YuL, Korotaeva TV, Loginova EYu, et al. The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register. Terapevticheskii Arkhiv. 2021;93(5): 573-580. (In Russ.).Andreasson S, Södergren A. Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis. Clin Rheumatol. 2025 Oct;44(10):3787-3799. doi: 10.1007/s10067-025-07637-z.Andreasson S, Södergren A. Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis. Clin Rheumatol. 2025 Oct;44(10):3787-3799. doi: 10.1007/s10067-025-07637-z.Czarnecka A, Purzycka-Bohdan D, Zablotna M, et al. Considerations of the Genetic Background of Obesity among Patients with Psoriasis. Genes (Basel). 2023 Feb 26; 14(3):594. doi: 10.3390/genes14030594.Czarnecka A, Purzycka-Bohdan D, Zablotna M, et al. Considerations of the Genetic Background of Obesity among Patients with Psoriasis. Genes (Basel). 2023 Feb 26; 14(3):594. doi: 10.3390/genes14030594.Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016 Dec; 12(12):1299-1308. doi: 10.1080/1744666X.2016.1201423.Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016 Dec; 12(12):1299-1308. doi: 10.1080/1744666X.2016.1201423.Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207.Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207.Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci. 2010 Aug; 59(2):143-5. doi: 10.1016/j.jdermsci.2010.06.004.Takahashi H, Honma M, Ishida-Yamamoto A, Iizuka H. Adiponectin and leptin modulate cell proliferation and cytokine secretion of normal human keratinocytes and T lymphocytes. J Dermatol Sci. 2010 Aug; 59(2):143-5. doi: 10.1016/j.jdermsci.2010.06.004.Jung MY, Kim HS, Hong HJ, et al. Adiponectin induces dendritic cell activation via PLC /JNK/NF-κB pathways, leading to Th1 and Th17 polarization. J Immunol. 2012 Mar 15;188(6):2592-601. doi: 10.4049/jimmunol.1102588.Jung MY, Kim HS, Hong HJ, et al. Adiponectin induces dendritic cell activation via PLC /JNK/NF-κB pathways, leading to Th1 and Th17 polarization. J Immunol. 2012 Mar 15;188(6):2592-601. doi: 10.4049/jimmunol.1102588.Wang Y, Huo J, Zhang D, et al. Chemerin/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-κB signaling. J Cell Biochem. 2019 Apr;120(4):6459-6470. doi: 10.1002/jcb.27936.Wang Y, Huo J, Zhang D, et al. Chemerin/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-κB signaling. J Cell Biochem. 2019 Apr;120(4):6459-6470. doi: 10.1002/jcb.27936.Sluczanowska-Glabowska S, Staniszewska M, Marchlewicz M, et al. Adiponectin, Leptin and Resistin in Patients with Psoriasis. J Clin Med. 2023 Jan 13;12(2):663. doi: 10.3390/jcm12020663.Sluczanowska-Glabowska S, Staniszewska M, Marchlewicz M, et al. Adiponectin, Leptin and Resistin in Patients with Psoriasis. J Clin Med. 2023 Jan 13;12(2):663. doi: 10.3390/jcm12020663.Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207.Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207.Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1007-11. doi: 10.1111/j.1468-3083.2011.04065.x.Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1007-11. doi: 10.1111/j.1468-3083.2011.04065.x.Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factoralpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4. doi: 10.1111/j.1468-3083.2007.02429.x.Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factoralpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4. doi: 10.1111/j.1468-3083.2007.02429.x.Jin D, Sun J, Huang J, et al. TNF-α reduces g0s2 expression and stimulates lipolysis through PPAR-γ inhibition in 3T3-L1 adipocytes. Cytokine. 2014 Oct;69(2):196-205. doi: 10.1016/j.cyto.2014.06.005.Jin D, Sun J, Huang J, et al. TNF-α reduces g0s2 expression and stimulates lipolysis through PPAR-γ inhibition in 3T3-L1 adipocytes. Cytokine. 2014 Oct;69(2):196-205. doi: 10.1016/j.cyto.2014.06.005.Pina T, Genre F, Lopez-Mejias R, et al. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1995-2001. doi: 10.1111/jdv.13131.Pina T, Genre F, Lopez-Mejias R, et al. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy. J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1995-2001. doi: 10.1111/jdv.13131.Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014 Jun;73(6):1157-62. doi: 10.1136/annrheumdis-2012-202812.Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014 Jun;73(6):1157-62. doi: 10.1136/annrheumdis-2012-202812.Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019 Jan 11;21(1):17. doi: 10.1186/s13075-019-1810-5.Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019 Jan 11;21(1):17. doi: 10.1186/s13075-019-1810-5.Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017 Dec;25(12):2068-2073. doi: 10.1002/oby.21955.Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017 Dec;25(12):2068-2073. doi: 10.1002/oby.21955.Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 2017 Apr 1; 152(4):344-349. doi: 10.1001/jamasurg.2016.4610.Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg. 2017 Apr 1; 152(4):344-349. doi: 10.1001/jamasurg.2016.4610.Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24:15:1431292. doi: 10.3389/fendo.2024.1431292.Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24:15:1431292. doi: 10.3389/fendo.2024.1431292.Bajic Z, Sobot T, Uletilovic S, et al. Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats. Can J Physiol Pharmacol. 2023 May 1;101(5):258-267. doi: 10.1139/cjpp-2022-0534.Bajic Z, Sobot T, Uletilovic S, et al. Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats. Can J Physiol Pharmacol. 2023 May 1;101(5):258-267. doi: 10.1139/cjpp-2022-0534.El-Shafey M, El-Agawy MSE, Eldosoky M, et al. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis. Front Endocrinol (Lausanne). 2022 Mar 18:13:862394. doi: 10.3389/fendo.2022.862394.El-Shafey M, El-Agawy MSE, Eldosoky M, et al. Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis. Front Endocrinol (Lausanne). 2022 Mar 18:13:862394. doi: 10.3389/fendo.2022.862394.Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug 23:12:721135. doi: 10.3389/fendo. 2021.721135.Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug 23:12:721135. doi: 10.3389/fendo. 2021.721135.Насонов ЕЛ, Паневин ТС, Трошина ЕА. Агонисты рецепторов глюкагоноподобного пептида-1: перспективы применения в ревматологии. Научно-практическая ревматология. 2024;62(2):135-144.Nasonov EL, Panevin TS, Troshina EA. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology. NauchnoPrakticheskaya Revmatologia. 2024;62(2): 135-144. (In Russ.).Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013 Feb;22(2):150-2. doi: 10.1111/exd.12081.Faurschou A, Pedersen J, Gyldenløve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013 Feb;22(2):150-2. doi: 10.1111/exd.12081.Atiquzzaman N, Razdolsky N, Parmar MS. GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management – current evidence and future outlook. Eur J Clin Pharmacol. 2025 Nov;81(11):1569-1581. doi: 10.1007/s00228-025-03898-4.Atiquzzaman N, Razdolsky N, Parmar MS. GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management – current evidence and future outlook. Eur J Clin Pharmacol. 2025 Nov;81(11):1569-1581. doi: 10.1007/s00228-025-03898-4.Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011 Nov;54(11):2745-54. doi: 10.1007/s00125-011-2232-3.Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011 Nov;54(11):2745-54. doi: 10.1007/s00125-011-2232-3.Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004.Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012 Feb;38(1):86-8. doi: 10.1016/j.diabet.2011.11.004.Faurschou A, Knop FK, Thyssen JP, et al. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014 Feb;51(1): 147-50. doi: 10.1007/s00592-011-0359-9.Faurschou A, Knop FK, Thyssen JP, et al. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014 Feb;51(1): 147-50. doi: 10.1007/s00592-011-0359-9.Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1440-3. doi: 10.1111/j.1468-3083.2012.04609.x.Ahern T, Tobin AM, Corrigan M, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1440-3. doi: 10.1111/j.1468-3083.2012.04609.x.Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective caseseries study. Br J Dermatol. 2014 Jul;171(1): 155-61. doi: 10.1111/bjd.12886.Buysschaert M, Baeck M, Preumont V, et al. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal γδ T-cell number: a prospective caseseries study. Br J Dermatol. 2014 Jul;171(1): 155-61. doi: 10.1111/bjd.12886.Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019 Apr:150:167-173. doi: 10.1016/j.diabres.2019.03.002.Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2019 Apr:150:167-173. doi: 10.1016/j.diabres.2019.03.002.Cai Y, Fleming C, Yan J. Dermal γδ T cells – a new player in the pathogenesis of psoriasis. Int Immunopharmacol. 2013 Jul; 16(3):388-91. doi: 10.1016/j.intimp.2013. 02.018.Cai Y, Fleming C, Yan J. Dermal γδ T cells – a new player in the pathogenesis of psoriasis. Int Immunopharmacol. 2013 Jul; 16(3):388-91. doi: 10.1016/j.intimp.2013. 02.018.Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients-a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629.Faurschou A, Gyldenløve M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients-a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):555-9. doi: 10.1111/jdv.12629.Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022 May;33(3):1299-1305. doi: 10.1080/09546634.2021.1882658.Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022 May;33(3):1299-1305. doi: 10.1080/09546634.2021.1882658.Nicolau J, Nadal A, Sanchis P, et al. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023 Oct 13;161(7):293-296. doi: 10.1016/j.medcli.2023.05.021.Nicolau J, Nadal A, Sanchis P, et al. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023 Oct 13;161(7):293-296. doi: 10.1016/j.medcli.2023.05.021.Коротаева ТВ, Трошина ЕА, Лила АМ и др. Эффективность лираглутида в комплексной терапии больных псориазом в сочетании с метаболическими нарушениями: метаанализ наблюдательных и контролируемых исследований. Ожирение и метаболизм. 2025;22(2):70-76.Korotaeva TV, Troshina EA, Lila AM, et al. Efficacy of liraglutide in combination therapy of patients with psoriasis combined with metabolic disorders: a meta-analysis of observational and controlled studies. Ozhirenie i metabolizm. 2025;22(2):70-76. (In Russ.).Nicolau J, Nadal A, Sanchis P, et al. Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control? Med Clin (Barc). 2025 Jun 13;164(11):106941. doi: 10.1016/j.medcli.2025.106941.Nicolau J, Nadal A, Sanchis P, et al. Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control? Med Clin (Barc). 2025 Jun 13;164(11):106941. doi: 10.1016/j.medcli.2025.106941.Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022 May;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392.Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022 May;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392.Nicolau J, Nadal A, Ros I, Masmiquel L. Effects of liraglutide among patients with psoriatic arthritis and obesity. Reumatol Clin (Engl Ed). 2025 Jan;21(1):501809. doi: 10.1016/j.reumae.2025.501809.Nicolau J, Nadal A, Ros I, Masmiquel L. Effects of liraglutide among patients with psoriatic arthritis and obesity. Reumatol Clin (Engl Ed). 2025 Jan;21(1):501809. doi: 10.1016/j.reumae.2025.501809.Costanzo G, Curatolo S, Busа B, et al. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021 Aug 1:2021:21-0007. doi: 10.1530/EDM-21-0007.Costanzo G, Curatolo S, Busа B, et al. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021 Aug 1:2021:21-0007. doi: 10.1530/EDM-21-0007.Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023 Aug 8;2023(3):23-0017. doi: 10.1530/EDM-23-0017.Malavazos AE, Meregalli C, Sorrentino F, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023 Aug 8;2023(3):23-0017. doi: 10.1530/EDM-23-0017.Nicolau J, Nadal A, Sanchis P, et al. Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study. Clin Exp Dermatol. 2026 Feb 24;51(3):442-450. doi: 10.1093/ced/llaf473.Nicolau J, Nadal A, Sanchis P, et al. Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study. Clin Exp Dermatol. 2026 Feb 24;51(3):442-450. doi: 10.1093/ced/llaf473.Petkovic-Dabi J, Binic I, Caric B, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025 Jan 1; 15(1):46. doi: 10.3390/biom15010046.Petkovic-Dabi J, Binic I, Caric B, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025 Jan 1; 15(1):46. doi: 10.3390/biom15010046.Gisondi P, Brigenti N, Bellinato F, Girolomoni G. Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity? J Eur Acad Dermatol Venereol. 2026 Jun;40(6):e460-e462. doi: 10.1111/jdv.70208.Gisondi P, Brigenti N, Bellinato F, Girolomoni G. Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity? J Eur Acad Dermatol Venereol. 2026 Jun;40(6):e460-e462. doi: 10.1111/jdv.70208.Круглова ЛС, Бридан-Ростовская АС, Шатохина ЕА. Опыт применения Нетакимаба и агониста ГПП1 у пациентов с псориазом и метаболическим синдромом. Медицинский алфавит. 2026;(3):28-34.Kruglova LS, Bridan-Rostovskaya AS, Shatokhina EA. Experience with Netakimab and a GLP1 agonist in patients with psoriasis and metabolic syndrome. Meditsinskii alfavit. 2026;(3):28-34. (In Russ.).Currado D, Trunfio F, Saracino F, et al. Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients. RMD Open. 2025 Jun 22;11(2):e005717. doi: 10.1136/rmdopen-2025-005717.Currado D, Trunfio F, Saracino F, et al. Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients. RMD Open. 2025 Jun 22;11(2):e005717. doi: 10.1136/rmdopen-2025-005717.Merola JF, Mease P, Kivitz A, et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Online ahead of print.Merola JF, Mease P, Kivitz A, et al. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Online ahead of print.Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709.Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709.

The authors declare that there are no conflicts of interest present.